SequelSEC

Solid Biosciences Inc. SLDB

Biological Products, (No Diagnostic Substances) · CIK 0001707502 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2020-12-31
Operating income
-$88.41M
Fiscal year ended 2020-12-31
Free cash flow
-$57.50M
Fiscal year ended 2020-12-31

Valuation, from the filing

Public float$317.70MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$3.23Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio9.76x82th
Revenue YoY growth-40.6%25th

Solid Biosciences Inc. (SLDB) reported revenue of $0 for the fiscal year ended 2020-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Solid Biosciences Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Solid Biosciences Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-31
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$88.41M
Net incomeUnavailable
Research & development$64.88M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$21.58M
Selling & marketingUnavailable

Balance

Solid Biosciences Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-31
Cash & equivalents$154.74M
Total assets$171.17M
Current assets$158.90M
Total liabilities$39.08M
Current liabilities$24.48M
Total equity incl. NCI$132.09M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$3.27M

Cash flow

Solid Biosciences Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-31
Operating cash flow-$56.60M
Capital expenditures$899.00K
Investing cash flow$6.60M
Financing cash flowUnavailable
Net change in cash$78.70M
Stock-based compensation$11.63M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Solid Biosciences Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-31
Free cash flow-$57.50M
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio6.49x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SLDB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-19View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.